51 Joe catches the tip of the needle .. the competition of the vaccine market "Blue Ocean" is hot

Competition for vaccine development by domestic and foreign drug companies is on track this year. In particular, national pharmaceutical companies are actively involved in the development of related technologies, such as newly established foreign affiliates and newly established vaccine subsidiaries.

GC Green Cross finalized the creation of a local company, CLEVO, in Seattle, Washington, USA, last May. Curebo, which is dedicated to developing vaccines in the United States, plans to conduct US clinical trials on the shingles vaccine, which GC Green Cross has completed its initial development. "We expect that clinical trials will begin this year," said a GC Green Cross official. "We will focus on the vaccine market in the United States based on the technology developed for the first time in Korea against chickenpox, influenza and hepatitis B.

National vaccine technology catches up with multinational pharmaceutical companies . Since GC Green Cross was able to locate influenza vaccines in 2009, Ji-Fu Flu is the leader in the national market, surpbading the products of multinational pharmaceutical companies. Foreign sales have exceeded 200 million US dollars (224 billion US dollars) by exporting to the southern hemisphere, exactly the opposite of the flu epidemic.

SK Chemicals created SK Bioscience on January 1 by spraying vaccines. More than 420 of SK Chemical's 1,600 employees have joined SK Bioscience. SK Chemicals has developed the world's second largest zoster vaccine, Skyjozer. Skyjojster, which began selling in December last year, posted sales of only 200 billion won in the first half of this year.

Meanwhile, the shingles vaccine was the only Merck product from a multinational pharmaceutical company. A SK Chemical representative said, "Our goal is to increase the share of the zoster vaccine to 50% this year." The global shingle market is estimated at $ 800 million (890 billion won), which is expected to double over the next 10 years. The vaccine market is likely to grow as well. SK Bioscience will focus on the development of premium vaccines such as cervical cancer and pediatric enteritis.

LG Chem Biotechnology Department has completed the development of the polio vaccine and is conducting clinical trials. Poliomyelitis vaccines are not developed domestically and depend entirely on imports.

National drug companies are actively developing "vaccines" for vaccines. The domestic vaccine market is growing rapidly. According to Korea's Food and Drug Administration, the national vaccine market grew at an average annual rate of 8 percent, from 48.7 billion won in 2012 to 556.3 billion won in 2016. The vaccine market is expected to grow quickly as higher quality vaccines, such as shingles, are released.

Vaccines are considered the main blue ocean market in the biotechnology industry. Globally, vaccines have been developed for only 28 types of diseases, including influenza. Of these, only about 14 types of vaccines are produced in Korea. Domestic and foreign drug companies are actively developing new vaccines as global trends in population aging and disease prevention change. "China must wait at least six months to be vaccinated against cervical cancer," said Kim Hak-ju, an badyst at a financial badyst firm specializing in the values securities.

Dissemination of Zikah-Mers … The Rise of the Voices Expressed by Sovereignty